Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Avacta Group plc ( (GB:AVCT) ) has provided an announcement.
Avacta Group plc has conditionally raised £10 million via an oversubscribed placing and director subscription of new ordinary shares at 63 pence each, representing about 3.6% of its existing share capital. The funds were raised through the issue of 15,000,000 placing shares and 873,016 subscription shares, with Zeus Capital acting as sole broker and bookrunner.
Non-executive directors Richard Hughes and David Bryant together invested approximately £550,000 in the subscription, while Zeus Capital also participated in the placing and will receive warrants over 4,364,457 shares, exercisable over five years at the issue price. The related party transactions, including director participation and the issuance of warrants to Zeus Capital, were reviewed by independent directors and deemed fair and reasonable, with admission of the new shares to AIM expected around 7 April 2026, taking the enlarged issued share capital to 456,288,511 shares.
The most recent analyst rating on (GB:AVCT) stock is a Hold with a £48.00 price target. To see the full list of analyst forecasts on Avacta Group plc stock, see the GB:AVCT Stock Forecast page.
Spark’s Take on AVCT Stock
According to Spark, TipRanks’ AI Analyst, AVCT is a Neutral.
Avacta Group plc’s overall stock score is primarily impacted by its weak financial performance and bearish technical indicators. While there is some progress in clinical programs, financial constraints and lack of partnerships remain significant risks. The stock’s valuation is unattractive due to negative earnings and no dividend yield.
To see Spark’s full report on AVCT stock, click here.
More about Avacta Group plc
Avacta Therapeutics, part of Avacta Group plc, is a clinical-stage life sciences company focused on oncology. It is developing its proprietary pre|CISION® tumor-activated drug delivery platform, which uses a fibroblast activation protein (FAP)-based peptide system to concentrate highly potent cancer therapies in the tumor microenvironment while reducing systemic toxicity.
Average Trading Volume: 1,635,904
Technical Sentiment Signal: Buy
Current Market Cap: £299.6M
See more data about AVCT stock on TipRanks’ Stock Analysis page.